Evaluation of immunogenicity, efficacy and safety of GP40041 compared to Humulin® NPH in patients with type 2 diabetes mellitus
Background. GP40041 is a biosimilar to Humulin® NPH. GP40041 is registered and administrated in Russia since 2004. However, due to changes in the regulatory requirements for biosimilar insulin development programme, we have conducted additional clinical trials of GP40041 including a comparative clin...
Main Authors: | A. G. Zalevskaya, A. A. Mosikian, O. V. Afonkina, R. V. Drai |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2019-08-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/420 |
Similar Items
-
Effects of combined treatment with rosiglitazone and NPH insulin on carbohydrate metabolism in patients with type 2 diabetes mellitus
by: O A Kandalintseva, et al.
Published: (2008-12-01) -
Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies
by: Bin Sun, et al.
Published: (2021-06-01) -
Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus
by: Nelson Rassi, et al. -
Custo-utilidade da insulina glargina e insulina isófana (NPH) para o tratamento de pacientes com diabetes mellitus tipo 2 atendidos no Sistema Único de Saúde do Município de Recife
by: CARVALHO, Dayse Cabral de
Published: (2017) -
Effect of insulin glargine on glycemic control in adolescents with type 1-diabetes
by: Hassan M. Mona, et al.
Published: (2015-06-01)